
|Videos|November 1, 2021
Botox shows favorable long-term outcomes for OAB and urinary incontinence
Author(s)Urology Times staff
“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.
Advertisement
In this video, David A. Ginsberg, MD, discusses the background and findings of the study, “Long-term, repeat treatments with onabotulinumtoxinA (Botox) are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










